DUSA Pharmaceuticals Inc., the wholly owned subsidiary of Sun Pharmaceutical Industries announced that DUSA has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera
Pharma GmbH, and Biofrontera AG (together known as “Biofrontera”) from using DUSA's confidential and proprietary trade secret information.
DUSA had filed a lawsuit against the Biofrontera defendants earlier this year in the US District Court for the District of Massachusetts. The lawsuit alleges trade secret misappropriation and patent infringement of
DUSA's photodynamic therapy (“PDT”) patents, US 9,723,991 and US 8,216,289, covering DUSA's product, LEVULAN® KERASTICK® (aminolevulinic acid HCl) for topical solution, 20% used with DUSA's BLU-U Blue Light Photodynamic Therapy Illuminator.